NOVA is a leading Healthtech company which simulates in silico clinical trials in virtual patient populations for bio-pharma companies with a need to accelerate and de-risk their R&D. With over a decade of experience and multiple commercial projects with biotech and pharma companies, NOVA has developed a unique in silico clinical trial simulation platform called JINKO. With BioModeling, Artificial Intelligence and Virtual Populations at the heart of NOVA's innovative approach, the platform takes its name from the fortunate homonymic collision of the Japanese words for 'artificial and 'population'.
Best-in-class clinical trial simulation and disease modeling platform
NOVA's unique positioning relies mainly on being able to simulate in silico clinical trials in the same conditions as in vivo (same endpoints, clinical outcomes, patient population) and offering a tool that breaks the internal silo between modeling experts and R&D teams. Providing our sponsors with a very high degree of quality and validation, with a fully Whitebox approach for in-depth auditing. Each model component is seamlessly traceable from the model documentation back to each primary source of information to ensure full auditability.
Their team of expert biomodelers apply standard operating procedures, from knowledge curation to computational model calibration and validation, which have been refined over the past decade through multiple projects in various therapeutic areas. Mechanistic models of disease and virtual patients are aimed at helping drug developers generate new insights and manage the complexity of human biology. NOVA's methodology enables users to predict a target or drug candidate's clinical benefit on virtual patient subgroups potentially years before pivotal trials can be conducted, by combining disease models, drug candidate submodels and virtual patients. The range of applications from early research through to market access for a single disease model is described below:
Discovery
Streamline target identification & secure proof of concept
- Explore efficacy of various targets & combinations treatments
- Explore transability from animal models to humans
- Prioritize compounds into clinic
Clinical Development
Optimize trial design & capture best responders
- Explore various regimens dose, number of administration(s) per day, time between administrations, duration of treatment
- Identify subgroups of optimal responders /theranostics biomarkers
- Expand the conclusions extracted from regular clinical trials, in order to address all the specific expectations from HTA bodies in particular
Market Access
- Expand the conclusions extracted from regular clinical trials, in order to address all the specific expectations from HTA bodies in particular
NOVA's modeling expertise combines mathematical models of disease and treatments with virtual patients into an integrated clinical trial simulation platform called JINKO. In a nutshell, disease and treatment computational models are built based on knowledge extracted from literature and data. Then, to simulate a trial, these models are run on virtual patients to predict the clinical efficacy of new drugs at the population level before trials on human subjects take place.
About Clinical Trials Innovation Programme 2022
Clinical Trials Innovation Programme is an invitation-only, premium event bringing together a mix of clinical research professionals and service providers in one stimulating environment.
Join us face to face to learn from the best in the drug development industry and have an opportunity to learn from their experiences. With an agenda covering the future of Clinical trials and drug development post COVID, Clinical Trials Innovation Programme 2022 will feature tailored sessions presented by the leading experts from across the globe.
We are bringing together the best in the industry to help you learn and grow, and accelerate your drug development journey. The experts will include thought leaders and visionaries from Danish Medicines Agency, Bayer Pharmaceuticals, AstraZeneca, The Janssen Pharmaceutical Companies of Johnson & Johnson, Travere Therapeutics, Biogen, Vifor Pharma, Medical Products Agency and much more.